ZIAGEN
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZIAGEN is an oral small-molecule antiretroviral approved in 1998 by GSK. The drug's specific mechanism of action and indications are not detailed in available data, but its 25-year market presence suggests established use in a chronic disease state. It is formulated as a tablet for convenient oral administration.
$0.112MPart D
LOE ApproachingDeclining
Low commercial intensity with approaching loss of exclusivity suggests a mature brand with minimal ongoing team expansion or hiring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
ZIAGEN® Post-marketing Surveillance
Started Nov 2010
671 enrolled
Infection, Human Immunodeficiency Virus I
Career Relevance
ZIAGEN offers limited career growth opportunities given its approaching loss of exclusivity and minimal commercial momentum ($112K Part D spend, 176 claims). Roles on this product are typically focused on managed decline and generic transition support rather than expansion.
Brand Manager
Worked on ZIAGEN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.